Europe Ranks Third in Global mRNA Race

A new study of 557 trials shows Europe is a primary hub for mRNA innovation as the field pivots from COVID-19 to oncology and rare diseases

16 Mar 2026

In the early 2020s, mRNA was the sudden, sharp answer to a global crisis. Today, it is becoming a slow, methodical business. A study published in February 2026 in Human Vaccines and Immunotherapeutics shows that the fever of the pandemic has cooled into a broader, more complex pursuit. Of 557 trials tracked since 2002, Europe now hosts 90. This puts the continent in third place, trailing North America and Asia, but the raw numbers hide a more interesting shift in intent.

The technology is no longer just a shield against viruses. While infectious diseases once claimed nearly three quarters of all mRNA research, that dominance is fading. Scientists are now turning the "software of life" toward oncology, rare conditions, and autoimmune disorders. In 2025, early-stage exploratory research accounted for 78% of new trial registrations. This is the experimental phase of a technology trying to find its second act.

For European policymakers, this trend is a test of infrastructure. The continent is betting on high-end, individualized medicine rather than mass production. In Britain, the NHS Cancer Vaccine Launch Pad is attempting to link patients with experimental treatments. In Germany, biotech firms are refining platforms for personalized cancer vaccines. The commercial world remains optimistic; private companies fund over half of all registered trials globally.

However, the transition from vaccines to "boutique" medicine brings awkward trade-offs. mRNA treatments for rare diseases are expensive to make and difficult to distribute. High costs mean these trials are almost exclusively the playground of wealthy nations, leaving a gap in global health equity that remains unfilled. Furthermore, most of these candidates are years away from a pharmacy shelf.

The momentum is undeniable, yet the path is steep. With several large trials expected to report results across 2026 and 2027, Europe’s 90 trials represent a solid foundation. If the science holds, the continent will be more than a mere participant in the mRNA story; it will be a primary setting. Success now depends less on the speed of an emergency and more on the patience of the laboratory.